Browse > Article
http://dx.doi.org/10.5808/GI.2008.6.4.192

Erythropoietin-producing Human Hepatocellular Carcinoma Receptor B1 Polymorphisms are Associated with HBV-infected Chronic Liver Disease and Hepatocellular Carcinoma in a Korean Population  

Kim, Kyoung-Yeon (Medical Genomics Laboratory, Graduate School of Life Science and Biotechnology, Pochon CHA University)
Lee, Seung-Ku (Medical Genomics Laboratory, Graduate School of Life Science and Biotechnology, Pochon CHA University)
Kim, Min-Ho (Medical Genomics Laboratory, Graduate School of Life Science and Biotechnology, Pochon CHA University)
Cheong, Jae-Youn (Department of Gastroenterology, Genomic Research Center for Gastroenterology, Ajou University School of Medicine)
Cho, Sung-Won (Department of Gastroenterology, Genomic Research Center for Gastroenterology, Ajou University School of Medicine)
Yang, Kap-Seok (Macrogen Inc.)
Kwack, Kyu-Bum (Medical Genomics Laboratory, Graduate School of Life Science and Biotechnology, Pochon CHA University)
Publication Information
Genomics & Informatics / v.6, no.4, 2008 , pp. 192-201 More about this Journal
Abstract
Erythropoietin-producing human hepatocellular carcinoma receptor B1 (EPHB1) is a member of the Eph family of receptor tyrosine kinases that mediate vascular system development. Eph receptor overexpression has been observed in various cancers and is related to the malignant transformation, metastasis, and differentiation of cancers, including hepatocellular carcinoma (HCC). Eph receptors regulate cell migration and attachment to the extracellular matrix by modulating integrin activity. EphrinB1, the ligand of EPHB1, has been shown to regulate HCC carcinogenesis. Here, we sought to determine whether EPHB1 polymorphisms are associated with hepatitis B virus (HBV)-infected liver diseases, including chronic liver disease (CLD) and HCC. We genotyped 26 EPHB1 single nucleotide polymorphisms (SNPs) in 399 Korean CLD, HCC, and LD (CLD+HCC) cases and seroconverted controls (HBV clearance, CLE) using the GoldenGate assay. Two SNPs (rs6793828 and rs11717042) and 1 haplotype that were composed of these SNPs were associated with an increased risk for CLD, HCC, and LD (CLD+HCC) compared with CLE. Haplotypes that could be associated with HBV-infected liver diseases by affecting downstream signaling were located in the Eph tyrosine kinase domain of EPHB1. Therefore, we suggest that EPHB1 SNPs, haplotypes, and diplotypes may be genetic markers for the progression of HBV-associated acute hepatitis to CLD and HCC.
Keywords
chronic liver disease; hepatocellular carcinoma; Eph receptor; angiogenesis; polymorphism;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Sy, S.M., Wong, N., Lai, P.B., To, K.F., and Johnson, P.J. (2005). Regional over-representations on chromosomes 1q, 3q and 7q in the progression of hepatitis B virus-related hepatocellular carcinoma. Mod. Pathol. 18, 686- 692   DOI   ScienceOn
2 Tang, X.X., Brodeur, G.M., Campling, B.G., and Ikegaki, N. (1999). Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin. Cancer Res. 5, 455-460
3 Stein, E., Huynh-Do, U., Lane, A.A., Cerretti, D.P., and Daniel, T.O. (1998). Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J. Biol. Chem. 273, 1303-1308   DOI   ScienceOn
4 Ng, D., Hu, N., Hu, Y., Wang, C., Giffen, C., Tang, Z.Z., Han, X.Y., Yang, H.H., Lee, M.P., Goldstein, A.M., and Taylor, P.R. (2008). Replication of a genome-wide casecontrol study of esophageal squamous cell carcinoma .Int. J. Cancer. 123, 1610-1615   DOI   ScienceOn
5 Oh, S.H., and Park, T.S. (2007). Regression Models for Haplotype-Based Association Studies. Genomics & Informatics 5, 19-23   과학기술학회마을
6 Pasquale, E.B. (2008). Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38-52   DOI   ScienceOn
7 Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I.M., Matlashewski, G., and Banks, L. (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393, 229-234   DOI   ScienceOn
8 Sun, H.C., and Tang, Z.Y. (2004). Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J. Cancer. Res. Clin. Oncol. 130, 307-319   DOI
9 Valentini, F.A., Nelson, P.P., and Besson, G.R. (2003). Detrusor activity and motor neurons firing during micturition: analysis by means of modeling of urodynamic tracings. Ann. Readapt. Med. Phys. 46, 594-600   DOI
10 Yoon, Y.J., Chang, H.Y., Ahn, S.H., Kim, J.K., Park, Y.K., Kang, D.R., Park, J.Y., Myoung, S.M., Kim do, Y., Chon, C.Y., and Han, K.H. (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29, 1192-1196   DOI   ScienceOn
11 Dutt, A., and Beroukhim, R. (2007). Single nucleotide polymorphism array analysis of cancer. Curr. Opin. Oncol. 19, 43-49   DOI   ScienceOn
12 Hood, J.D., and Cheresh, D.A. (2002). Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100   DOI   ScienceOn
13 Fu, X., Wang, Q., Chen, X., Huang, X., Cao, L., Tan, H., Li, W., Zhang, L., Bi, J., Su, Q., and Chen, L. (2008). Expression patterns and polymorphisms of PTCH in Chinese hepatocellular carcinoma patients. Exp. Mol. Pathol. 84, 195-199   DOI   ScienceOn
14 Himanen, J.P., and Nikolov, D.B. (2003a). Eph receptors and ephrins. Int. J. Biochem. Cell. Biol. 35, 130-134   DOI   ScienceOn
15 Himanen, J.P., and Nikolov, D.B. (2003b). Eph signaling: a structural view. Trends. Neurosci. 26, 46-51   DOI   ScienceOn
16 Hu, N., Wang, C., Hu, Y., Yang, H.H., Giffen, C., Tang, Z.Z., Han, X.Y., Goldstein, A.M., Emmert-Buck, M.R., Buetow, K.H., Taylor, P.R., and Lee, M.P. (2005). Genome-wide association study in esophageal cancer using GeneChip mapping 10K array. Cancer Res. 65, 2542-2546   DOI   ScienceOn
17 Kalo, M.S., and Pasquale, E.B. (1999). Signal transfer by Eph receptors. Cell Tissue Res. 298, 1-9   DOI
18 Lesnick, T.G., Papapetropoulos, S., Mash, D.C., Ffrench- Mullen, J., Shehadeh, L., de Andrade, M., Henley, J.R., Rocca, W.A., Ahlskog, J.E., and Maraganore, D.M. (2007). A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet. 3, e98   DOI   ScienceOn
19 Lewis, C.M. (2002). Genetic association studies: design, analysis and interpretation. Brief Bioinform. 3, 146-153   DOI   ScienceOn
20 Marrero, J.A. (2006). Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 22, 248-253   DOI   ScienceOn
21 Clifford, N., Smith, L.M., Powell, J., Gattenlohner, S., Marx, A., and O'Connor, R. (2008). The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J. Cell. Biochem. (in press)
22 Castano, J., Davalos, V., Schwartz, S., Jr., and Arango, D. (2008). EPH receptors in cancer. Histol. Histopathol. 23, 1011-1023
23 Calin, G.A., Trapasso, F., Shimizu, M., et al. (2005). Familial cancer associated with a polymorphism in ARLTS1. N. Engl. J. Med. 352, 1667-1676   DOI   ScienceOn
24 Collier, J., and Sherman, M. (1998). Screening for hepatocellular carcinoma. Hepatology 27, 273-278   DOI   ScienceOn
25 Adams, R.H., Wilkinson, G.A., Weiss, C., Diella, F., Gale, N.W., Deutsch, U., Risau, W., and Klein, R. (1999). Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes. Dev. 13, 295-306   DOI
26 Brantley-Sieders, D.M., and Chen, J. (2004). Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 7, 17-28   DOI   ScienceOn
27 Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., and Cheresh, D.A. (1994b). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164   DOI   ScienceOn
28 Dodelet, V.C., and Pasquale, E.B. (2000). Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19, 5614-5619   DOI
29 Kim, I., Ryu, Y.S., Kwak, H.J., Ahn, S.Y., Oh, J.L., Yancopoulos, G.D., Gale, N.W., and Koh, G.Y. (2002). EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB. J. 16, 1126-1128   DOI
30 Drake, C.J., Cheresh, D.A., and Little, C.D. (1995). An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell. Sci. 108(Pt 7), 2655-2661
31 Kim, Y.U., Kim, S.H., Jin, H., Park, Y.K., Ji, M.H., and Kim, Y.J. (2008). The Korean HapMap Project Website. Genomics & Informatics 6, 91-94   과학기술학회마을   DOI
32 Kiyohara, C., and Yoshimasu, K. (2007). Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int. J. Med. Sci. 4, 59-71
33 Kojima, T., Chang, J.H., and Azar, D.T. (2007). Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am. J. Pathol. 170, 764-773   DOI   ScienceOn
34 Klein, N.P., and Schneider, R.J. (1997). Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol. Cell. Biol. 17, 6427-6436   DOI
35 Kullander, K., and Klein, R. (2002). Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell. Biol. 3, 475-486   DOI   ScienceOn
36 Lee, S.K., Kim, M.H., Cheong, J.Y., Cho, S.W., Yang, S.J., and Kwack, K. (2008). Integrin alpha V polymorphisms and haplotypes in a Korean population are associated with susceptibility to chronic hepatitis and hepatocellular carcinoma. Liver. Int. (in press)
37 Truelove, A.L., Oleksyk, T.K., Shrestha, S., Thio, C.L., Goedert, J.J., Donfield, S.M., Kirk, G.D., Thomas, D.L., O'Brien, S.J., and Smith, M.W. (2008). Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int. J. Immunogenet. 35, 255-264   DOI   ScienceOn
38 Brooks, P.C., Clark, R.A., and Cheresh, D.A. (1994a). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571   DOI
39 Chang, Q., Jorgensen, C., Pawson, T., and Hedley, D.W. (2008). Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br. J. Cancer 99, 1074-1082   DOI   ScienceOn
40 Velazquez, R.F., Rodriguez, M., Navascues, C.A., Linares, A., Perez, R., Sotorrios, N.G., Martinez, I., and Rodrigo, L. (2003). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37, 520-527   DOI   ScienceOn
41 Yoon, S.Y., Jeong, M.J., Yoo, J., Lee, K.I., Kwon, B.M., Lim, D.S., Lee, C.E., Park, Y.M., and Han, M.Y. (2001). Grb2 dominantly associates with dynamin II in human hepatocellular carcinoma HepG2 cells. J. Cell. Biochem. 84, 150-155   DOI   ScienceOn
42 Xiong, X.D., Fang, J.H., Qiu, F.E., Zhao, J., Cheng, J., Yuan, Y., Li, S.P., and Zhuang, S.M. (2008). A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutat. Res. 643, 70-74   DOI
43 Zeng, Z.Y., Xiong, W., Zhou, Y.H., Li, X.L., and Li, G.Y. (2006). Advances in high-density whole genome-wide single nucleotide polymorphism array in cancer research. Ai Zheng 25, 1454-1458
44 Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 94, 153-156   DOI   ScienceOn
45 Huynh-Do, U., Stein, E., Lane, A.A., Liu, H., Cerretti, D.P., and Daniel, T.O. (1999). Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO. J. 18, 2165-2173   DOI   ScienceOn
46 Kikkawa, H., Kaihou, M., Horaguchi, N., Uchida, T., Imafuku, H., Takiguchi, A., Yamazaki, Y., Koike, C., Kuruto, R., Kakiuchi, T., Tsukada, H., Takada, Y., Matsuura, N., and Oku, N. (2002). Role of integrin alpha( v)beta3 in the early phase of liver metastasis: PET and IVM analyses. Clin. Exp. Metastasis 19, 717-725   DOI
47 Sawai, Y., Tamura, S., Fukui, K., Ito, N., Imanaka, K., Saeki, A., Sakuda, S., Kiso, S., and Matsuzawa, Y. (2003). Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization. J. Hepatol. 39, 991-996   DOI   ScienceOn
48 Pang, R.W., and Poon, R.T. (2007). From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72 Suppl 1, 30-44   DOI
49 Oshima, T., Akaike, M., Yoshihara, K., Shiozawa, M., Yamamoto, N., Sato, T., Akihito, N., Nagano, Y., Fujii, S., Kunisaki, C., Wada, N., Rino, Y., Tanaka, K., Masuda, M., and Imada, T. (2008). Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer. Int. J. Oncol. 33, 573-577